- Details
- Category: 2024
- Published: 28 February 2024
- Last Updated: 27 August 2024
- Hits: 2027
CDC Monthly Respiratory disease and Influenza Bulletin for Year 2024
In July 2024, National Influenza Surveillance sentinel sites collected 583 samples for Influenza and SARS-CoV-2 virus testing. There were 448 Severe Acute Respiratory Illness (SARI) samples at nine sites in five provinces (Figure 1). Of all the SARI samples collected for testing, 123 (27.4%) tested positive for influenza viruses, out of which 83 tested positive for A/H3N2, 29 tested positive for A/H1N1pdm, 9 tested positive for B/Vic, 1 tested positive for A/H5N1, and 1 tested positive for A/H1N1pdm co-infected with A/H3N2. Eight (1.8%) SARI samples were positive for SARS-CoV-2. There were 135 samples from Influenza-Like Illness (ILI) Surveillance at 17 sites in 16 provinces (Figure 1). 54 (39.2%) were positive for influenza, out of which 38 tested positive for A/H3N2, nine tested positive for A/H1N1pdm, and seven tested positive for B/Vic. Eight (6.6%) ILI samples were positive for SARS-CoV-2.
In June 2024, National Influenza Surveillance sentinel sites collected 458 samples for Influenza and SARS-CoV-2 virus testing. There were 331 Severe Acute Respiratory Illness (SARI) samples at nine sites in five provinces (Figure 1). Of all the SARI samples collected for testing, 48 (14.5%) tested positive for influenza viruses, out of which 29 tested positive for A/H3N2, 12 tested positive for B/Vic, and 7 tested positive for A/H1N1pdm. 49 (14.8%) SARI samples were positive for SARS-CoV-2. There were 127 samples from Influenza-Like Illness (ILI) Surveillance at 17 sites in 16 provinces (Figure 1). 14 (11.0%) were positive for influenza, out of which nine tested positive for A/H3N2, and three tested positive for A/H1N1pdm, and two tested positive for B/Vic. 32 (25.1%) ILI samples were positive for SARS-CoV-2.
In May 2024, National Influenza Surveillance sentinel sites collected 445 samples for Influenza and SARS-CoV-2 virus testing. There were 299 samples from Severe Acute Respiratory Illness (SARI) at nine sites in five provinces (Figure 1). Of all the SARI samples collected for testing, 24 (8.0%) tested positive for influenza virus, out of which 13 tested positive for A/H3N2, 10 tested positive for B/Vic, and 1 tested positive for A/H1N1pdm. 27 (9.0%) SARI samples were positive for SARS-CoV-2. There were 132 samples from Influenza-Like Illness (ILI) Surveillance at 17 sites in 16 provinces (Figure 1). 13 (9.8%) were positive for influenza, out of which eight tested positive for A/H3N2, and five tested positive for B/Vic. 32 ILI samples (24.2%) were positive for SARS-CoV-2.
In Apr 2024, National Influenza Surveillance sentinel sites collected 371 samples for Influenza and SARS-CoV-2 virus testing. There were 252 samples from Severe Acute Respiratory Illness (SARI) at nine sites in five provinces (Figure 1). Of all the SARI samples collected for testing, 16 (6.3%) tested positive for influenza virus, out of which 11 tested positive for B/Vic, and five tested positive for A/H3N2. Two (0.8%) SARI samples were positive for SARS-CoV-2. There were 119 samples from Influenza-Like Illness (ILI) Surveillance at 17 sites in 16 provinces (Figure 1). 16 (13.4%) were positive for influenza, out of which eight tested positive for A/H3N2, seven tested positive for B/Vic, and one tested positive for A/H1N1pdm. Three ILI samples (2.5%) were positive for SARS CoV-2.
In March 2024, National Influenza Surveillance sentinel sites collected 420 samples for Influenza and SARS-CoV-2 virus testing. There were 293 samples from Severe Acute Respiratory Illness (SARI) at nine sites in five provinces (Figure 1). Of all the SARI samples collected for testing, 26 (8.9%) tested positive for influenza virus, of which 23 tested positive for B/Vic, two tested positive for A/H3N2, and one tested positive for A/H1N1pdm. Four (1.4%) SARI samples were positive for SARS-CoV-2. There were 127 samples from Influenza-Like Illness (ILI) Surveillance at 17 sites in 16 provinces (Figure 1). 16 (12.5%) were positive for influenza, out of which 10 tested positive for B/Vic, three tested positive for A/H3N2, and three tested positive for A/H1N1pdm. Two ILI samples (1.5%) were positive for SARS-CoV-2.
In February 2024, National Influenza Surveillance sentinel sites collected 558 samples for Influenza and SARS-CoV-2 virus testing. There were 406 samples from Severe Acute Respiratory Illness (SARI) at 9 sites in 5 provinces (Figure 1). There were 152 samples from Influenza-Like Illness (ILI) Surveillance at 17 sites in 16 provinces (Figure 1). Among 406 SARI specimens, 48 (11.8%) tested positive for influenza virus, of which 40 tested positive for B/Vic, five tested positive for A/H3N2, two tested positive for A/H1N1pdm, and one tested positive for A/H5N1. Of all the SARI samples collected for testing, six (1.5%) were positive for SARS-CoV-2. Of 152 ILI specimens, 27 (17.8%) were positive for influenza, out of which 24 tested positive for B/Vic, and three tested positive for A/H3N2. Seven ILI samples (4.6%) were positive for SARS-CoV-2.
In January 2024, National Influenza Surveillance sentinel sites collected 423 samples for Influenza and SARS-CoV-2 virus testing. There were 324 samples from Severe Acute Respiratory Illness (SARI) at 9 sites in 5 provinces (Figure 1). There were 99 samples from Influenza-Like Illness (ILI) Surveillance at 17 sites in 16 provinces (Figure 1). Among 324 SARI specimens, 22 (6.8%) tested positive for influenza virus, of which 16 tested positive for B/Vic, 5 tested positive for A/H3N2, and 1 tested positive for A/H1N1pdm. Out of all the SARI samples collected for testing, 33 (10.2%) were positive for SARS-CoV-2. Of 99 ILI specimens, 17 (17.2%) were positive for influenza, of which 12 tested positive for B/Vic, and 5 tested positive for A/H3N2. 11 ILI samples (11.1%) were positive for SARS-CoV-2.